agenT-797: Clinical Trials

4 trials of agenT-797, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Recruiting 1

Follow agenT-797: new trials by email Literature Review of agenT-797 trials Research Report on agenT-797

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies
Phase 1RecruitingUniversity of Wisconsin, Madison222026-11-012026-11-12
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
agenT-797, Approved ICIs - Tumor, Solid
Phase 1CompletedMiNK Therapeutics342022-01-282024-04-24
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
agenT-797 - Relapsed/Refractory Multiple Myeloma
Phase 1CompletedMiNK Therapeutics132021-03-292023-06-06
A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS
agenT-797 - Respiratory Distress Syndrome, Adult
Phase 1CompletedMiNK Therapeutics202020-09-212025-12-30

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms (1)  ·  Respiratory Distress Syndrome (1)

Sponsors

MiNK Therapeutics (3)  ·  University of Wisconsin, Madison (1)

Countries

United States (4)

Top investigators

Hongtau Liu, MD, PhD (1)

Results publications

PMID 38321023